摘要
在老人和阿尔茨海默病(AD)中,神经炎症已经作为认知功能下降的重要原因出现。在肥胖和糖尿病患者中观察到了慢性低度炎症,这是阿尔茨海默病的重要危险因素。因此,我们研究了大鼠脑海马在Zucker糖尿病脂肪(ZDF)样品的炎症标志物。通路特异性基因表达谱显示氧化应激和炎症基因的表达显著增加。Western blot分析进一步表明,NF-κB的活化,有缺陷的CREB的水平磷酸化,以及保护CREB靶蛋白水平降低,包括在糖尿病大鼠脑样本的Bcl-2, BDNF和BIRC3,所有这一切都是相关的阿尔茨海默病病理学。基于胰高血糖素样肽-1(GLP-1)治疗是控制血糖水平的2型糖尿病患者中的有效性,我们测试了胰高血糖素样肽-1体内试验,为期10周,ZDF大鼠糖尿病脑使用Alogliptin,它是二肽基肽酶抑制剂。在糖尿病大鼠中,Alogliptin增加了胰高血糖素样肽-1的125%循环水平和降低了59%血糖。有缺陷的信号在海马标本治疗的糖尿病大鼠CREB归一化导致CREB目标表达增加。在胰岛β细胞和脑中的胰高血糖素样肽-1双行动表明,在老年糖尿病患者身上肠促胰岛素治疗可降低糖尿病患者的认知功能下降,也被用于治疗阿尔茨海默病人的潜在药物
关键词: 脑
Current Alzheimer Research
Title:Glucagon-Like Peptide-1-Mediated Modulation of Inflammatory Pathways in the Diabetic Brain: Relevance to Alzheimer’s Disease
Volume: 13 Issue: 12
Author(s): LiMei Qin, Thomas Chong, Richard Rodriguez, Subbiah Pugazhenthi
Affiliation:
关键词: 脑
摘要: Neuroinflammation has emerged as an important cause of cognitive decline during aging and in Alzheimer’s disease (AD). Chronic low-grade inflammation is observed in obesity and diabetes, which are important risk factors for AD. Therefore, we examined the markers of inflammation in the brain hippocampal samples of Zucker diabetic fatty (ZDF) rats. Pathway-specific gene expression profiling revealed significant increases in the expression of oxidative stress and inflammatory genes. Western blot analysis further showed the activation of NF-kB, defective CREB phosphorylation, and decreases in the levels of neuroprotective CREB target proteins, including Bcl-2, BDNF, and BIRC3 in the diabetic rat brain samples, all of which are related to AD pathology. As therapies based on glucagon-like peptide-1 (GLP-1) are effective in controlling blood glucose levels in type 2 diabetic patients, we tested the in vivo actions of GLP-1 in the diabetic brain by a 10-wk treatment of ZDF rats with alogliptin, an inhibitor of dipeptidyl peptidase. Alogliptin increased the circulating levels of GLP-1 by 125% and decreased blood glucose in diabetic rats by 59%. Normalization of defective signaling to CREB in the hippocampal samples of treated diabetic rats resulted in the increased expression of CREB targets. Dual actions of GLP-1 in the pancreatic beta cells and in the brain suggest that incretin therapies may reduce cognitive decline in the aging diabetic patients and also have the potential to be used in treating Alzheimer’s patients.
Export Options
About this article
Cite this article as:
LiMei Qin, Thomas Chong, Richard Rodriguez, Subbiah Pugazhenthi , Glucagon-Like Peptide-1-Mediated Modulation of Inflammatory Pathways in the Diabetic Brain: Relevance to Alzheimer’s Disease, Current Alzheimer Research 2016; 13 (12) . https://dx.doi.org/10.2174/1567205013666160401114751
DOI https://dx.doi.org/10.2174/1567205013666160401114751 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Primary Lung Lymphoma
Current Drug Targets - Inflammation & Allergy Phage Display Applications for Molecular Imaging
Current Pharmaceutical Biotechnology Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling
Current Drug Targets How Much is Enough? Modulation of Dose-Response Curve for Steroid Receptor-Regulated Gene Expression by Changing Concentrations of Transcription Factor
Current Topics in Medicinal Chemistry Recent Advances in the Development of Multi-Kinase Inhibitors
Mini-Reviews in Medicinal Chemistry Predicted Contributions of Flavin-containing Monooxygenases to the N-oxygenation of Drug Candidates Based on their Estimated Base Dissociation Constants
Current Drug Metabolism Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence
Current Pharmaceutical Design Heat Shock Proteins: Therapeutic Perspectives in Inflammatory Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Withdrawal Notice: Comparison of Pharmaceutical Effect of Alemtuzumab and Natalizumab and Their Side Effects in Treatment of Various Stages of Multiple Sclerosis Patients
CNS & Neurological Disorders - Drug Targets Computer-Assisted Methods in Chemical Toxicity Prediction
Mini-Reviews in Medicinal Chemistry Nitrone Derivatives as Therapeutics: From Chemical Modification to Specific-targeting
Current Topics in Medicinal Chemistry Beyond the Reproductive Effect of Sex Steroids: Their Role During Immunity to Helminth Parasite Infections
Mini-Reviews in Medicinal Chemistry Phytoestrogens and Prostate Cancer
Current Drug Targets Novel Therapeutic Targets for Somatostatin in Inflammatory Chronic Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Blockade of Insulin-Like Growth Factor Type-1 Receptor with Cixutumumab (IMC-A12): A Novel Approach to Treatment for Multiple Cancers
Current Drug Targets Disease Modifying Drugs in Multiple Sclerosis: Mechanisms of Action and New Drugs in the Horizon
CNS & Neurological Disorders - Drug Targets A Knock-Down Cell-Based Study for the Functional Analysis of Chloride Intracellular Channel 1 (CLIC1): Integrated Proteomics and Microarray Study
Protein & Peptide Letters Effect of Administration Route on the Biodistribution and Shedding of Replication-Deficient AAV2: A Qualitative Modelling Approach
Current Gene Therapy Small Molecule Inhibitors of NF-κB and JAK/STAT Signal Transduction Pathways as Promising Anti-Inflammatory Therapeutics
Mini-Reviews in Medicinal Chemistry Bioinformatic Tools Identify Chromosome-Specific DNA Probes and Facilitate Risk Assessment by Detecting Aneusomies in Extra-embryonic Tissues
Current Genomics